

VENTAVIS PATIENT ENROLLMENT FORM

Prescription	VENTAVIS® (iloprost) Inhalation Solution 2.5 mcg or 5 mcg (10 mcg/mL) inhalation via I-neb® AAD® System, as tolerated. 6 to 9 times per day during waking hours. Start with 2.5 mcg × 1. If tolerated, go to 5 mcg (10 mcg/mL) ongoing. If not tolerated, resume 2.5 mcg. If patient is maintained at 5 mcg (10 mcg/mL) dose and repeatedly experiences extended treatment times, consider transitioning to 5 mcg (20 mcg/mL). If patient is maintained at VENTAVIS 5 mcg (10 mcg/mL) for 1 month, consider transitioning to VENTAVIS 5 mcg (20 mcg/mL) starting at month 2, unless contacted by physician. Or please provide dosing instructions: Dispense 1-month supply. Refills (select 1): 0 1 2 3 4 5 6 7 8 9 10 11 Send one (1)* I-neb AAD System if this is an initial order. *If the patient resides in a remote area that does not allow for timely delivery (delivery within 8 hours), two (2) I-neb AAD Systems will be dispensed. Nursing services requested. Skilled nursing visit for patient education related to therapy and disease state, administration of medication as prescribed, and assessment of general status and response to therapy. One to 3 visits to be provided for patient training. Patient training: Specialty pharmacy to conduct initial patient training; initial training with I-neb Insight breathing monitor required. Or please provide patient training instructions: Characteristics and the section of the				PO Box 826, South San Francisco, CA 94083-0826 Phone 1-866-ACTELION (1-866-228-3546) or Fax 1-866-279-0669 Ship-to directions: Physician's office Patient's home Hospital If shipped to physician's office, physician accepts delivery on behalf of patient for administration in office. Address (no PO Box): City: State: ZIP: Ship Attn: I certify that the above therapy ordered is medically necessary and that the information provided is accurate to the best of my knowledge. Further, I hereby authorize Actelion Pathways® ("the Hub") to transmit this prescription to the dispensing pharmacy. PHYSICIAN SIGNATURE (REQUIRED TO VALIDATE PRESCRIPTION). Physician attests this is his/her legal signature (NO STAMPS). PRESCRIPTIONS MUST BE FAXED.			
	Follow-up nursing visits as ordered by physician to ensure patient is proficient in medication use and I-neb AAD System administration. Check this box to order a nursing visit to conduct an I-neb Insight download to measure patient compliance and assess patient breathing technique. Week(s) post therapy initiation. PHYSICIAN SIGNATURE (no stamps) (dispense as written) DATE							
REQUI	RED: PLEASE PROVIDE COPIES OF PATIENT'S CURRENT N	MFDIO	CALINSUE	RANG				•
Specialty Pharmacy	Indicate specialty pharmacy preference: If no preference is indicated, this referral will be sent to the appropriate specialty pt the patient's existing insurance benefits.				Benefit ve	rification	only. Do not ser	nd drug at this time. n visit only at this time.
Physician Information	Name: DEA #:							NPI #:
	Name of facility: MD specialty							Tax ID #:
	Contact name and phone #: State license			#:				Phone #:
	Address: City:			State: ZIP:				Fax #:
Patient Information	Name:							DOB:
	Address: City:						State:	ZIP:
	Preferred language, if not English:				e #:			Sex: Male Female
	Caregiver name:				ionship:			Alternate phone #:
Insurance Information	Primary insurance company:							Phone #:
	Policyholder name:				D #:			Group/policy #:
	Secondary insurance name:							Phone #:
	Policyholder name:			ID #:	ID#:			Group/policy #:
	Prescription coverage name: Phone #:			ID #:	ID #:			Group/policy #:
By signing below, I authorize my healthcare providers, pharmacies, health plans, or payers ("my health care organizations") to share personal and health information about me related to my Actelion PAH therapies ("my information") with Actelion Pharmaceuticals US, Inc., its affiliates, agents, and contractors (collectively, "Actelion"). I understand that once my information is shared with Actelion, my information may be protected by certain state privacy laws but not by federal health privacy laws, and may be redisclosed by Actelion. Actelion agrees to protect my information and to use and share it only for the reasons listed below. I understand that my pharmacy compensation in connection with sharing my information with Actelion, an order for Actelion to: (1) contact me or my healthcare organizations, or others I have identified, about my disease or treatment; (2) confirm my health plan eligibility and benefits, identify other payers for my therapy, or determine whether I may be eligible for assistance programs; (3) enroll me in Actelion PAH therapies—related programs and provide therapy access support services; (4) perform analyses or improve or develop products, services, programs, or treatment related to my disease; (5) provide me by any means of communication, including by e-mail, mail, or telephone (including voicemail), with information to educate or inform me about Actelion PAH therapies and ways to help me maintain my prescribed treatment; and (6) use and disclose my information for safety reasons or as required by law. I understand that if I do not sign this form, I will still be eligible for health plan benefits and my treatment and payment for my treatment by my healthcare providers and pharmacy will not be affected, but I will not have access to the Actelion Pars-70277 and may cancel it by writing a letter saying I cancel my Authorization at any time by calling 1-866-875-0277 and may cancel it by writing a letter saying I cancel my Authorization and it will not apply to prior actions taken by Acteli								
Patient Name (Print): Patient or Parent/Guardian/Representative Date:						signer'	orm is signed by soi s legal authority to a	act for the patient: